---
title: "SFPM: Pediatric Lung Heat Cough and Wheezing Oral Solution approved to conduct clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261387719.md"
description: "According to the Zhitong Finance APP, SFPM announced that its wholly-owned subsidiary Heilongjiang SFPM Co., Ltd. recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration, approving the clinical trial of the pediatric lung heat cough and asthma oral solution for use in children with acute bronchitis"
datetime: "2025-10-16T08:00:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261387719.md)
  - [en](https://longbridge.com/en/news/261387719.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261387719.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/261387719.md) | [繁體中文](https://longbridge.com/zh-HK/news/261387719.md)


# SFPM: Pediatric Lung Heat Cough and Wheezing Oral Solution approved to conduct clinical trials

According to the Zhitong Finance APP, SFPM (002737.SZ) announced that its wholly-owned subsidiary Heilongjiang SFPM Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, which approves the clinical trial of the pediatric lung heat cough and asthma oral solution for use in children with acute bronchitis

### Related Stocks

- [SFPM (002737.CN)](https://longbridge.com/en/quote/002737.CN.md)

## Related News & Research

- [Zydus Lifesciences Drug Desidustat Approved for Renal Anaemia in China](https://longbridge.com/en/news/279245927.md)
- [Cutia Therapeutics Receives Chinese Regulatory Approval to Begin Trials of Hair Loss Drug](https://longbridge.com/en/news/279185356.md)
- [Ofcom Calls on Tech Firms to Enforce Stronger Child Safety Measures Online](https://longbridge.com/en/news/278893852.md)
- [Justice for Kids Co-Founder Justin Grosz Elected to NACC Board](https://longbridge.com/en/news/278752448.md)
- [Jacobio Pharma: Differentiated Pan-KRAS Profile, Multiple Clinical Catalysts, and Solid Balance Sheet Underscore Buy Rating](https://longbridge.com/en/news/278909908.md)